Table 4.
Best overall response rate (ORR) to ASP8273 among patients with non‐small‐cell lung cancer by epidermal growth factor receptor T790M mutation status, phase I
| T790M+ (n = 23) | T790M− (n = 6) | T790M unknown (n = 16) | |
|---|---|---|---|
| CR, n (%) | 0 (0) | 0 (0) | 0 (0) |
| PR, n (%) | 12 (52) | 2 (33) | 8 (50) |
| SD, n (%) | 10 (44) | 1 (17) | 7 (44) |
| ORR, % (95% CI)a | 52 (30.6, 73.2) | 33 (4.3, 77.7) | 50 (24.7, 75.3) |
| DCR, % (95% CI)a | 96 (78.1, 99.9) | 50 (11.8, 88.2) | 94 (69.8, 99.8) |
Data presented as n (%).
a
Based on exact binomial confidence interval (CI; Clopper‐Pearson).
CR, complete response; DCR, disease control rate; PR, partial response; SD, stable disease.